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The indirect hemagglutination assay routinely used to detect antibodies to Burkholderia pseudomallei was
modified to detect cross-reactivity of antibodies to B. pseudomallei, B. mallei, and B. thailandensis antigens. We
demonstrate a lack of cross-reactivity between B. pseudomallei and B. thailandensis but marked cross-reactivity
between B. pseudomallei and B. mallei.
Burkholderia pseudomallei is the causative agent of melioid-
osis and a recognized biothreat agent. The organism is present
in mud and pooled surface water in Southeast Asia and north-
ern Australia, where natural infection is acquired following
inoculation or inhalation (11). Culture of B. pseudomallei is the
gold standard for the diagnosis of melioidosis. However, sero-
logical testing is commonly used, particularly in resource-poor
regions that lack microbiological culture facilities. Serological
testing may also be used as an epidemiological marker of
exposure in regions where melioidosis is not known to be
endemic and in patients (such as returned travelers or military
personnel) from areas where melioidosis is not endemic to
investigate suspected exposure to B. pseudomallei or Burkhold-
eria mallei (the causative agent of glanders).
In areas where melioidosis is endemic, high rates of back-
ground seropositivity have been noted (4, 8); this limits the
specificity of the most commonly used indirect hemagglutina-
tion assay (IHA). Seropositivity may be due to prior exposure
to B. pseudomallei or exposure to the antigenically similar but
rarely pathogenic B. thailandensis which is present in the en-
vironment in Thailand. This may also explain the higher rate of
seropositivity seen in Thailand than that seen in Australia,
where B. thailandensis is not present (4). The aim of this study
was to define whether patients with culture-proven melioidosis
have antibodies with cross-reactivity to B. pseudomallei, B.
thailandensis, or B. mallei antigens presented in a modified
IHA.
Patients with melioidosis were prospectively recruited over a
5-month period between June and October 2004 by a study
team based at Sappasithiprasong Hospital, Ubon Ratchathani,
northeast Thailand. Patients presenting with febrile illnesses
were identified by active surveillance of the medical and inten-
sive care wards. Culture of B. pseudomallei from any sample
was considered diagnostic for melioidosis (5). Patients were
excluded if they were 14 years of age or declined to partici-
pate. Ethical approval was obtained from the Ministry of Pub-
lic Health, Royal Government of Thailand.
Pooled antigens were prepared from the following isolates:
(i) B. pseudomallei clinical isolates 199a and 207a, obtained
from patients with melioidosis in northeast Thailand; (ii) B.
thailandensis isolates E27, E32, and E256, obtained from soil in
northeast Thailand; and (iii) B. mallei isolates EY2233 (kindly
provided by Sumalee Tungpredabkul, Faculty of Science, Ma-
hidol University) and ATCC 23344. A loopful of each isolate
was inoculated into 5 ml Trypticase soy broth and incubated
for 18 h with shaking at 37°C in air, after which 200 l was
spread onto 30 plates of either Columbia agar (for B.
pseudomallei and B. thailandensis) or Columbia agar plus 4%
glycerol (for B. mallei). Bacteria were harvested after incuba-
tion for 72 h at 37°C in air, suspended in 15 ml phosphate-
buffered saline, vortexed vigorously, and then autoclaved at
121°C for 15 min. Preparations were centrifuged at 4,000 rpm
for 30 min, the supernatants were filtered through a Millipore
0.22-m filter, phenol was added (0.5%), and the preparation
was stored at 4°C until use. An IHA was then performed as
previously described (1). Growth of isolates prior to harvest
and preparation of antigen represent a departure from the
previously reported method in which bacteria are incubated in
Rice medium at 37°C in air for 14 days prior to autoclaving,
centrifugation, and filtration, as described above. In view of
this difference, the B. pseudomallei IHA titers were initially
compared between the two methods. Overall IHA titers were
not significantly different between the two groups. Seven of 117
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sera (5.9%) gave IHA titers that were 2 dilutions different
between the methods (five samples were 2 dilutions different,
and two samples had a 3-dilution difference); of these titers,
three were higher using the conventional method, and four
were higher using the modified method. We propose that
growth of bacteria on agar plates prior to antigen preparation
for IHA is a reasonable alterative to prolonged growth in broth
culture.
Sera from 117 patients with culture-confirmed melioidosis
were evaluated. Patient ages ranged from 15 to 82 years (me-
dian, 48.5 years; interquartile range [IQR], 38 to 57); 56 pa-
tients (48%) were female. The majority of patients were rice
farmers (79%), and 70% had diabetes mellitus. Infection was
associated with septic shock in 22 patients (19%), and the
overall in-hospital mortality was 28%.
The B. pseudomallei titers ranged from 0 to 1:20,480 (me-
dian, 1:320; IQR, 1:80 to 1:1,280), and those for B. mallei
ranged from 0 to 1:10,240 (median, 1:160; IQR, 1:40 to 1:640).
There was significant cross-reactivity between the two assays
(Spearman’s   0.78, P  0.0001 [Fig. 1]). The IHA titers
were identical between the IHAs using B. pseudomallei or B.
mallei antigens in 46 (39%) of the 117 cases. The titer was
FIG. 1. IHA titers of (A) B. mallei and (B) B. thailandensis versus B. pseudomallei in patients with melioidosis. Each dot represents one or more
patients.
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greater with the B. pseudomallei IHA than with the B. mallei
IHA in 57 cases and less in 14 cases. Antibodies recognizing B.
thailandensis were not detected in 98 (84%) samples. Of the
remainder, 14 samples had a titer of 1:10, one had a titer of
1:20, three had a titer of 1:80, and one had a titer of 1:1,280
(the B. pseudomallei titer in this case was 1:20,480). There was
no significant cross-reactivity between the B. thailandensis as-
say and those based on B. pseudomallei (Spearman’s   0.17,
P  0.06) and B. mallei antigens (Spearman’s   0.09, P 
0.35); the borderline P value in the case of B. pseudomallei was
entirely due to the single high B. thailandensis case mentioned
above.
The finding of cross-reactivity of B. mallei antigens by anti-
bodies raised against B. pseudomallei is consistent with previ-
ous studies demonstrating antigenic relatedness between the
two species (2). In addition, there is increasing evidence of a
close phylogenetic relationship based on similarities in the
genome sequence and multilocus sequence typing (6, 7, 9). It is
unlikely that our patient group had been exposed to B. mallei
previously, as human glanders is not recognized to occur in
Thailand.
However, our patient population is likely to be repeatedly
exposed to both B. thailandensis and B. pseudomallei, which are
both present in soil in northeast Thailand (10). We found that
there was little detectable cross-reactivity between B. thailan-
densis and B. pseudomallei antigens by the IHA. The generally
absent or very low titers to B. thailandensis in our patient
population indicate that environmental exposure to this organ-
ism is not very immunogenic or that these antibodies are not
recognized by the IHA; in this way, B. thailandensis differs from
B. pseudomallei, for which background seropositivity is a major
problem in areas of endemicity. This study suggests that expo-
sure of individuals to B. thailandensis is unlikely to interfere
with the results from the B. pseudomallei IHA.
Some antigens, such as lipopolysaccharide, are known to be
conserved between these Burkholderia species (3), while others
are immunologically unique (12). A limitation of the IHA is
that the antigens generated are poorly characterized. It is gen-
erally assumed that the use of multiple strains would result in
a broad representation of antigens, but cell-free supernatant is
likely to be depleted of many of the major cell surface-associ-
ated antigens.
The explanation for the different rates of seropositivity be-
tween Australia and Thailand remains unclear. It is unlikely
that the intensity of exposure, maintaining seropositivity in
Southeast Asian patients, is responsible, as the rates of sero-
positivity were higher in immigrants to Australia from South-
east Asia (4). However, it is possible that intense exposure
earlier in life may result in a prolonged seropositivity. Differ-
ences in immunological responses to B. pseudomallei in Asian
and Australian patients have not been described, but variations
in Th1/Th2 responses may be important. Finally, the IHA is a
poorly standardized test with different isolates (typically local
clinical strains) used in Australia and Thailand; the effect of
these differences has not been defined.
Future publication of the B. thailandensis genome sequence
will shed new light on the similarities and degree of homology
between these saprophytic Burkholderia species. We conclude
that the B. pseudomallei IHA is unlikely to be confounded by
antibodies to B. thailandensis, but that this assay is unable to
distinguish between infection by B. pseudomallei and infection
by B. mallei.
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